Trial Profile
A Phase 1, Open-label Study to Evaluate the Effect of Lapatinib, a BCRP Inhibitor, on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Receiving Hemodialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enarodustat (Primary) ; Lapatinib
- Indications Anaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Akros Pharma
- 10 May 2019 Results assessing the PK of Lapatinib in ESRD patients on maintenance hemodialysis compared with data in 37 healthy subjects in 3 separate studies, published in the Journal of Clinical Pharmacology
- 27 Apr 2016 Status changed from recruiting to completed.
- 24 Oct 2015 New trial record